Further obtained structural information of this protein and its interactions with ATGL will aid in the future development of drugs to inhibit the G0S2 proteins binding to adipose triglyceride lipase and create a possible effective therapy against NAFLD. The gene discussed is PNPLA2; the disease is metabolic dysfunction-associated steatotic liver disease.